Your browser doesn't support javascript.
A pooled testing strategy for identifying SARS-CoV-2 at low prevalence.
Mutesa, Leon; Ndishimye, Pacifique; Butera, Yvan; Souopgui, Jacob; Uwineza, Annette; Rutayisire, Robert; Ndoricimpaye, Ella Larissa; Musoni, Emile; Rujeni, Nadine; Nyatanyi, Thierry; Ntagwabira, Edouard; Semakula, Muhammed; Musanabaganwa, Clarisse; Nyamwasa, Daniel; Ndashimye, Maurice; Ujeneza, Eva; Mwikarago, Ivan Emile; Muvunyi, Claude Mambo; Mazarati, Jean Baptiste; Nsanzimana, Sabin; Turok, Neil; Ndifon, Wilfred.
  • Mutesa L; Centre for Human Genetics, College of Medicine and Health Sciences, University of Rwanda, Kigali, Rwanda.
  • Ndishimye P; Rwanda Joint Task Force COVID-19, Rwanda Biomedical Centre, Ministry of Health, Kigali, Rwanda.
  • Butera Y; Rwanda Joint Task Force COVID-19, Rwanda Biomedical Centre, Ministry of Health, Kigali, Rwanda.
  • Souopgui J; African Institute for Mathematical Sciences, Kigali, Rwanda.
  • Uwineza A; Centre for Human Genetics, College of Medicine and Health Sciences, University of Rwanda, Kigali, Rwanda.
  • Rutayisire R; Rwanda Joint Task Force COVID-19, Rwanda Biomedical Centre, Ministry of Health, Kigali, Rwanda.
  • Ndoricimpaye EL; Centre for Human Genetics, College of Medicine and Health Sciences, University of Rwanda, Kigali, Rwanda.
  • Musoni E; Rwanda Joint Task Force COVID-19, Rwanda Biomedical Centre, Ministry of Health, Kigali, Rwanda.
  • Rujeni N; Department of Molecular Biology, Institute of Biology and Molecular Medicine, IBMM, Université Libre de Bruxelles, Gosselies, Belgium.
  • Nyatanyi T; Centre for Human Genetics, College of Medicine and Health Sciences, University of Rwanda, Kigali, Rwanda.
  • Ntagwabira E; Rwanda Joint Task Force COVID-19, Rwanda Biomedical Centre, Ministry of Health, Kigali, Rwanda.
  • Semakula M; Centre for Human Genetics, College of Medicine and Health Sciences, University of Rwanda, Kigali, Rwanda.
  • Musanabaganwa C; Rwanda Joint Task Force COVID-19, Rwanda Biomedical Centre, Ministry of Health, Kigali, Rwanda.
  • Nyamwasa D; Rwanda Joint Task Force COVID-19, Rwanda Biomedical Centre, Ministry of Health, Kigali, Rwanda.
  • Ndashimye M; Rwanda Joint Task Force COVID-19, Rwanda Biomedical Centre, Ministry of Health, Kigali, Rwanda.
  • Ujeneza E; Rwanda Joint Task Force COVID-19, Rwanda Biomedical Centre, Ministry of Health, Kigali, Rwanda.
  • Mwikarago IE; Rwanda Joint Task Force COVID-19, Rwanda Biomedical Centre, Ministry of Health, Kigali, Rwanda.
  • Muvunyi CM; Rwanda Joint Task Force COVID-19, Rwanda Biomedical Centre, Ministry of Health, Kigali, Rwanda.
  • Mazarati JB; Rwanda Joint Task Force COVID-19, Rwanda Biomedical Centre, Ministry of Health, Kigali, Rwanda.
  • Nsanzimana S; Rwanda Joint Task Force COVID-19, Rwanda Biomedical Centre, Ministry of Health, Kigali, Rwanda.
  • Turok N; Rwanda Joint Task Force COVID-19, Rwanda Biomedical Centre, Ministry of Health, Kigali, Rwanda.
  • Ndifon W; Rwanda Joint Task Force COVID-19, Rwanda Biomedical Centre, Ministry of Health, Kigali, Rwanda.
Nature ; 589(7841): 276-280, 2021 01.
Article in English | MEDLINE | ID: covidwho-1065892
ABSTRACT
Suppressing infections of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) will probably require the rapid identification and isolation of individuals infected with the virus on an ongoing basis. Reverse-transcription polymerase chain reaction (RT-PCR) tests are accurate but costly, which makes the regular testing of every individual expensive. These costs are a challenge for all countries around the world, but particularly for low-to-middle-income countries. Cost reductions can be achieved by pooling (or combining) subsamples and testing them in groups1-7. A balance must be struck between increasing the group size and retaining test sensitivity, as sample dilution increases the likelihood of false-negative test results for individuals with a low viral load in the sampled region at the time of the test8. Similarly, minimizing the number of tests to reduce costs must be balanced against minimizing the time that testing takes, to reduce the spread of the infection. Here we propose an algorithm for pooling subsamples based on the geometry of a hypercube that, at low prevalence, accurately identifies individuals infected with SARS-CoV-2 in a small number of tests and few rounds of testing. We discuss the optimal group size and explain why, given the highly infectious nature of the disease, largely parallel searches are preferred. We report proof-of-concept experiments in which a positive subsample was detected even when diluted 100-fold with negative subsamples (compared with 30-48-fold dilutions described in previous studies9-11). We quantify the loss of sensitivity due to dilution and discuss how it may be mitigated by the frequent re-testing of groups, for example. With the use of these methods, the cost of mass testing could be reduced by a large factor. At low prevalence, the costs decrease in rough proportion to the prevalence. Field trials of our approach are under way in Rwanda and South Africa. The use of group testing on a massive scale to monitor infection rates closely and continually in a population, along with the rapid and effective isolation of people with SARS-CoV-2 infections, provides a promising pathway towards the long-term control of coronavirus disease 2019 (COVID-19).
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Population Surveillance / COVID-19 Nucleic Acid Testing / SARS-CoV-2 / COVID-19 Type of study: Diagnostic study / Experimental Studies / Observational study / Randomized controlled trials Topics: Long Covid Limits: Humans Country/Region as subject: Africa Language: English Journal: Nature Year: 2021 Document Type: Article Affiliation country: S41586-020-2885-5

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Population Surveillance / COVID-19 Nucleic Acid Testing / SARS-CoV-2 / COVID-19 Type of study: Diagnostic study / Experimental Studies / Observational study / Randomized controlled trials Topics: Long Covid Limits: Humans Country/Region as subject: Africa Language: English Journal: Nature Year: 2021 Document Type: Article Affiliation country: S41586-020-2885-5